Carmel, United States
Sudo Biosciences, founded in 2020 and headquartered in the United States, is a burgeoning force in the biopharmaceutical sector. With a focused mission encapsulated by its slogan, "Developing precision TYK2 therapeutics," the company is committed to delivering innovative, best-in-class medicines aimed at transforming patients’ lives.
The company zeroes in on the tyrosine kinase 2 (TYK2) pseudokinase domain, a critical component in cytokine signaling pathways linked to various immune-mediated inflammatory conditions. This targeted approach places Sudo Biosciences at the forefront of addressing unmet medical needs in diseases driven by dysregulated immune responses.
The company's progress and potential did not go unnoticed in the investment community, securing a $30.00M Series B investment on 01 January 2024. Esteemed investors, including Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises, back this venture, signifying strong confidence in its innovative pursuits.
